Cerevel Therapeutics Holdings, Inc.

NasdaqCM:CERE Rapport sur les actions

Capitalisation boursière : US$8.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cerevel Therapeutics Holdings Bilan de santé

Santé financière contrôle des critères 5/6

Cerevel Therapeutics Holdings has a total shareholder equity of $564.5M and total debt of $451.9M, which brings its debt-to-equity ratio to 80.1%. Its total assets and total liabilities are $1.1B and $562.9M respectively.

Informations clés

80.1%

Ratio d'endettement

US$451.92m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$846.29m
Fonds propresUS$564.46m
Total du passifUS$562.89m
Total des actifsUS$1.13b

Mises à jour récentes de la santé financière

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Sep 26

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

Aug 12

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Aug 01

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Analyse de la situation financière

Passif à court terme: CERE's short term assets ($859.6M) exceed its short term liabilities ($84.1M).

Passif à long terme: CERE's short term assets ($859.6M) exceed its long term liabilities ($478.8M).


Historique et analyse du ratio d'endettement

Niveau d'endettement: CERE has more cash than its total debt.

Réduire la dette: CERE's debt to equity ratio has increased from 7.4% to 80.1% over the past 5 years.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CERE has sufficient cash runway for more than a year based on its current free cash flow.

Prévisions de trésorerie: CERE has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 31.2% each year.


Découvrir des entreprises saines